Can-Fite’s Namodenoson Meets Safety Endpoint in Phase IIa Pancreatic Cancer Trial

PUBT · 3d ago
Can-Fite’s Namodenoson Meets Safety Endpoint in Phase IIa Pancreatic Cancer Trial
  • Can-Fite BioPharma presented final Phase IIa results for namodenoson in advanced pancreatic cancer at ESMO 2026 in Madrid.
  • The trial met its primary safety endpoint; treatment-related adverse events were mild to moderate, with none requiring treatment changes.
  • Exploratory survival findings supported further clinical development, but the selected patient subgroup and lack of randomized comparison limit conclusions.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Can Fite Biofpharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610260700PRIMZONEFULLFEED9852892) on October 26, 2026, and is solely responsible for the information contained therein.